



FOR IMMEDIATE RELEASE

Millendo Therapeutics to Present at the Jefferies 2016 Healthcare Conference

ANN ARBOR, Mich., June 1, 2016 – [Millendo Therapeutics, Inc.](#), a company developing novel therapies for endocrine diseases caused by hormone dysregulation, today announced that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present a company overview at the Jefferies 2016 Healthcare Conference on Wednesday, June 8th, 2016 at 1:30 p.m. ET in New York City.

About Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to improve the quality of life for patients with orphan and specialty diseases with limited or no approved treatment options. Our clinical programs are designed to address:

- Polycystic Ovary Syndrome (PCOS) – the most common endocrine disease in women
- Adrenocortical Carcinoma (ACC) – a rare endocrine malignancy of the adrenal cortex
- Congenital Adrenal Hyperplasia (CAH) – a recessive genetic defect of cortisol synthesis
- Endogenous Cushing's Syndrome (CS) – a condition resulting from chronic cortisol excess

Our experienced team is committed to bringing these first-in-class therapies to market.

www.millendo.com

###

Media Contact:

Blair McCarthy Atkinson
MacDougall Biomedical Communications
Main: +1 781 235 3060
Direct: +1 812 454 6257
batkinson@macbiocom.com

Investor Contact:

Stephanie Ascher
Stern Investor Relations
+1 212 362 1200
stephanie@sternir.com